JP3227690B2 - Anti-neutrophil cytoplasmic antibody measurement method - Google Patents

Anti-neutrophil cytoplasmic antibody measurement method

Info

Publication number
JP3227690B2
JP3227690B2 JP08748494A JP8748494A JP3227690B2 JP 3227690 B2 JP3227690 B2 JP 3227690B2 JP 08748494 A JP08748494 A JP 08748494A JP 8748494 A JP8748494 A JP 8748494A JP 3227690 B2 JP3227690 B2 JP 3227690B2
Authority
JP
Japan
Prior art keywords
anca
antigen
buffer
mpo
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP08748494A
Other languages
Japanese (ja)
Other versions
JPH07280807A (en
Inventor
尚美 志田
信夫 西木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nipro Corp
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Priority to JP08748494A priority Critical patent/JP3227690B2/en
Publication of JPH07280807A publication Critical patent/JPH07280807A/en
Application granted granted Critical
Publication of JP3227690B2 publication Critical patent/JP3227690B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は、抗好中球細胞質抗体の
測定方法に関する。
The present invention relates to a method for measuring anti-neutrophil cytoplasmic antibodies.

【0002】[0002]

【従来の技術】抗好中球細胞質抗体(以下、ANCAと
いう)は蛍光抗体間接法(以下、IIF法という)によ
り検討され、その染色パターンから、細胞質が染色され
る(Cytoplasmic)-ANCA(以下、C−ANCAとい
う)と、核周辺が染色される(Perinuclear)-ANCA
(以下、P−ANCAという)の2つに分けられる。近
年、難治性の腎疾患であるウェゲナー肉芽腫症でC−A
NCAを測定することが早期診断に極めて有力になった
ことから、C−ANCAの測定が注目されるようになっ
た。しかしながらIIF法によるC−ANCAの測定は
手技および蛍光パターンの解釈にかなりの経験と熟練を
要するため日常の臨床検査には適さなかった。
2. Description of the Related Art Anti-neutrophil cytoplasmic antibodies (hereinafter, referred to as ANCA) are examined by a fluorescent antibody indirect method (hereinafter, referred to as IIF method), and cytoplasm is stained based on the staining pattern (Cytoplasmic) -ANCA (hereinafter, referred to as ANCA). , C-ANCA), the periphery of the nucleus is stained (Perinuclear) -ANCA
(Hereinafter, referred to as P-ANCA). In recent years, CA has been diagnosed with Wegener's granulomatosis, an intractable renal disease.
Since the measurement of NCA has become very effective for early diagnosis, the measurement of C-ANCA has attracted attention. However, the measurement of C-ANCA by the IIF method required considerable experience and skill in the interpretation of the technique and the fluorescence pattern and was not suitable for routine clinical examination.

【0003】その後、ヒト好中球のα顆粒でC−ANC
Aの対応抗原が同定されたことから、免疫学的作用を利
用した酵素免疫測定法(EIA法)による試薬が市販さ
れ、簡便かつ短時間でC−ANCAが測定されるように
なった。これは、合成樹脂製プレート等の表面に、ヒト
好中球から精製したC−ANCA抗原をコーティングさ
せ、乾燥状態にしたものに検体を入れ、発色剤を加えて
その吸光度を測定するものである。
[0003] Then, C-ANC was converted to α-granules of human neutrophils.
Since the corresponding antigen of A was identified, a reagent by enzyme immunoassay (EIA method) utilizing an immunological action was commercially available, and C-ANCA was measured simply and in a short time. In this method, a surface of a synthetic resin plate or the like is coated with a C-ANCA antigen purified from human neutrophils, a specimen is put in a dried state, a color former is added, and the absorbance is measured. .

【0004】[0004]

【発明が解決しようとする課題】しかしながら、C−A
NCA抗原はヒト好中球のα顆粒から精製するため、他
の物質が混在しうる可能性がある。ヒト好中球のα顆粒
中には、C−ANCA抗原以外に、ミエロペルオキシダ
ーゼ(以下、MPOという)、エラスターゼ、ラクトフ
ェリン、カテプシンGなどがあり、これらがC−ANC
A抗原と共存している。前述の共存抗原は検体中に存在
する抗ミエロペルオキシダーゼ抗体(以下、MPO−A
NCAという)などのC−ANCA以外の抗体と抗原抗
体反応を起こし、C−ANCA以外の物質を測定してし
まうという欠点がある。例えば、C−ANCAとMPO
−ANCAはその臨床的意義が異なるため、MPO−A
NCAよる非特異反応をC−ANCAとして測定するこ
とは診断を混乱させ問題であった。本発明はこの問題を
解決することである。
However, CA
Since the NCA antigen is purified from α-granules of human neutrophils, it is possible that other substances may be mixed. The α-granules of human neutrophils include, in addition to the C-ANCA antigen, myeloperoxidase (hereinafter referred to as MPO), elastase, lactoferrin, cathepsin G and the like.
Coexists with A antigen. The aforementioned coexisting antigen is an anti-myeloperoxidase antibody (hereinafter referred to as MPO-A) present in the sample.
However, there is a drawback that an antigen-antibody reaction occurs with an antibody other than C-ANCA such as NCA, and a substance other than C-ANCA is measured. For example, C-ANCA and MPO
-Since ANCA has different clinical significance, MPO-A
Measuring non-specific reactions by NCA as C-ANCA was confusing and problematic in diagnosis. The present invention is to solve this problem.

【0005】[0005]

【課題を解決するための手段】本発明は、抗原抗体反応
において抗好中球細胞質抗体の抗原と共存するミエロペ
ルオキシダーゼ抗原による非特異反応を抑制することを
特徴とする抗好中球細胞質抗体の測定方法である。本発
明において抗原抗体反応とは、検体中の抗好中球細胞質
抗体(C−ANCA)と試薬中のC−ANCA抗原の反
応をいう。また、本発明において抗好中球細胞質抗体の
測定方法としては、上記抗原抗体反応を利用したサンド
イッチ免疫測定法などがある。
SUMMARY OF THE INVENTION The present invention provides an anti-neutrophil cytoplasmic antibody characterized by suppressing a non-specific reaction caused by a myeloperoxidase antigen coexisting with an antigen of the anti-neutrophil cytoplasmic antibody in an antigen-antibody reaction. It is a measuring method. Departure
In the literature, the antigen-antibody reaction is defined as the anti-neutrophil cytoplasm in the sample.
Antibody (C-ANCA) and reaction of C-ANCA antigen in reagent
Say hello. In the present invention, the anti-neutrophil cytoplasmic antibody
As a measurement method, a sandwich method using the above antigen-antibody reaction was used.
Such as the switch immunoassay.

【0006】また本発明は、抗原抗体反応において抗好
中球細胞質抗体の抗原と共存するミエロペルオキシダー
ゼ抗原をpH調製した緩衝液で特異的に抑制することを
特徴とする抗好中球細胞質抗体の測定方法である。
The present invention also provides an anti-neutrophil cytoplasmic antibody characterized in that myeloperoxidase antigen coexisting with the antigen of the anti-neutrophil cytoplasmic antibody in the antigen-antibody reaction is specifically suppressed with a buffer solution adjusted to pH. It is a measuring method.

【0007】更にまた本発明は、抗原抗体反応において
抗好中球細胞質抗体の抗原と共存するミエロペルオキシ
ダーゼ抗原をpH2〜5に調製した緩衝液で特異的に抑
制することを特徴とする抗好中球細胞質抗体の測定方法
である。
Further, the present invention provides an anti-neutrophil, wherein the myeloperoxidase antigen coexisting with the antigen of the anti-neutrophil cytoplasmic antibody in the antigen-antibody reaction is specifically inhibited by a buffer adjusted to pH 2 to 5. This is a method for measuring sphere cytoplasmic antibodies.

【0008】緩衝液としては、クエン酸ナトリウム-リ
ン酸二水素ナトリウム緩衝液、クエン酸ナトリウム-塩
酸緩衝液、酢酸-水酸化ナトリウム緩衝液、コハク酸-水
酸化ナトリウム緩衝液、ββ-ジメチルグルタル酸-水酸
化ナトリウム緩衝液、グリシン-塩酸緩衝液、フタル酸
カリウム-塩酸緩衝液、クエン酸-クエン酸ナトリウム緩
衝液、酢酸-酢酸ナトリウム緩衝液、塩化カリウム-塩酸
緩衝液等のpH2〜5の範囲に維持できるものであれば
よい。
[0008] Buffers include sodium citrate-sodium dihydrogen phosphate buffer, sodium citrate-hydrochloric acid buffer, acetic acid-sodium hydroxide buffer, succinic acid-sodium hydroxide buffer, ββ-dimethylglutaric acid -PH range of sodium hydroxide buffer, glycine-hydrochloric acid buffer, potassium phthalate-hydrochloric acid buffer, citric acid-sodium citrate buffer, acetic acid-sodium acetate buffer, potassium chloride-hydrochloric acid buffer, etc. Anything can be maintained as long as it can be maintained.

【0009】有効pH領域は2〜5であるが、あまり酸
性に傾くとMPO抗原による非特異反応には有効であっ
ても目的とするC−ANCA抗原の活性が抑制されるた
め留意する必要がある。
Although the effective pH range is 2 to 5, it should be noted that if the pH is too acidic, the activity of the target C-ANCA antigen is suppressed even if it is effective for non-specific reaction by MPO antigen. is there.

【0010】C−ANCA抗原は不溶性担体に直接固相
化されても、別途加えてもよい。不溶性担体はガラス、
アガロース、デキストラン、セルロース、ポリアクリル
アミド、ポリスチレン、ホモポリペプチド、ラテック
ス、ポリカボーネート、ポリプロピレン、アミノアルキ
ルシリカガラス、シリコンゴム等が使用され、その表面
に共有結合法、イオン結合法、物理的吸着等によりC−
ANCA抗原を付着させた後乾燥させて固相化されてい
る。
[0010] The C-ANCA antigen may be immobilized directly on an insoluble carrier or may be added separately. The insoluble carrier is glass,
Agarose, dextran, cellulose, polyacrylamide, polystyrene, homopolypeptide, latex, polycarbonate, polypropylene, aminoalkyl silica glass, silicon rubber, etc. are used, and the surface is covalently bonded, ion bonded, physically adsorbed, etc. By C-
After attaching the ANCA antigen, it is dried and immobilized.

【0011】[0011]

【作用】上述のように、試薬中のC−ANCA抗原にp
H調製した緩衝液を添加することでC−ANCA抗原と
共存するMPO抗原による非特異反応が抑制されるの
で、MPO抗原により検体中のMPO−ANCAをC−
ANCAとして測定することなく、正確なC−ANCA
値を測定することが可能になる。
As described above, p-CCA is present on the C-ANCA antigen in the reagent.
H by adding the prepared buffer to C-ANCA antigen
Since non-specific reactions due to coexisting MPO antigens are suppressed , MPO-ANCA in the sample is reduced to C-
Accurate C-ANCA without measuring as ANCA
The value can be measured.

【0012】[0012]

【実施例】〔実施例1〕 正常ヒト好中球由来のC−ANCA抗原をヌンク社製の
マイクロプレート(96ウェル)に固定させたものを用
意した。クエン酸ナトリウム-リン酸二水素ナトリウム
緩衝液をpH3〜6に、塩化カリウム-塩酸緩衝液をp
H1〜2に調整した。各pHに調整した緩衝液を200
μl/ウェルずつマイクロプレートに分注し、25℃で6
0分間インキュベーションした。その後該緩衝液を除去
し、Tween20を含むリン酸緩衝液(pH7.2)
で洗浄した。次に、各々のウェルに検体としてリン酸緩
衝液(pH7.3)で75倍に希釈したC−ANCA含
有ヒト血清またはMPO−ANCA含有ヒト血清を20
0μl/ウェルずつ加え、25℃で60分間インキュベー
ション後、Tween20を含むリン酸緩衝液(pH
7.2)で洗浄を行った。さらにリン酸緩衝液(pH
7.3)で調整したオリオン社製のアルカリホスファタ
ーゼ標識抗ヒトIgG抗体を200μl/ウェルずつ分注
し、25℃で60分間インキュベーションした。その後
該緩衝液を除去し、Tween20を含むリン酸緩衝液
(pH7.2)で洗浄後、ジエタノールアミン-HCl
緩衝液(pH9.7)で調整したシグマ社製のp−ニト
ロフェニルリン酸二ナトリウムを発色剤として200μ
l/ウェルずつ加え、0分と60分との吸光度差を測定し
た。吸光度の測定は、コロナ社製、タイプMTP12
0のマイクロプレートリーダーを用い、405nmの波
長で測定した。なお、表中の測定値OD(Optica
l Dencity)は吸光度を表す。この結果を表
1に示す。
[ Example 1] A C-ANCA antigen derived from normal human neutrophils immobilized on a Nunc microplate (96 wells) was prepared. The pH of the sodium citrate-sodium dihydrogen phosphate buffer is adjusted to pH 3 to 6, and the pH of the potassium chloride-hydrochloric acid buffer is adjusted to p.
Adjusted to H1-2. Buffer solution adjusted to each pH is 200
Dispense μl / well into microplates at 25 ° C.
Incubated for 0 minutes. Thereafter, the buffer was removed, and a phosphate buffer containing Tween 20 (pH 7.2) was used.
And washed. Next, C-ANCA-containing human serum or MPO-ANCA-containing human serum diluted 75-fold with a phosphate buffer (pH 7.3) was added to each well as a sample.
After adding 0 μl / well and incubating at 25 ° C. for 60 minutes, a phosphate buffer containing Tween 20 (pH
Washing was performed in 7.2). In addition, phosphate buffer (pH
The alkaline phosphatase-labeled anti-human IgG antibody manufactured by Orion prepared in 7.3) was dispensed at 200 μl / well and incubated at 25 ° C. for 60 minutes. afterwards
The buffer was removed, washed with a phosphate buffer containing Tween 20 (pH 7.2), and then diethanolamine-HCl.
200 μl of Sigma disodium p-nitrophenyl phosphate adjusted with a buffer (pH 9.7)
1 / well was added, and the absorbance difference between 0 minute and 60 minutes was measured. The measurement of the absorbance difference is performed by Corona, type MTP12
The measurement was performed at a wavelength of 405 nm using a microplate reader of No. 0. The measured values OD (Optica) in the table
1 Density) represents the absorbance difference . Table 1 shows the results.

【0013】[0013]

【表1】 [Table 1]

【0014】pH調整していないC−ANCA測定試薬
中でのMPO−ANCA含有ヒト血清の値が0.848
である(比較例1)ことから、緩衝液はpH5以下から
抑制効果がみられる。一方、緩衝液をpH1の強酸に調
製した場合、MPO−ANCAの非特異反応は著しく抑
制されるが、同時にC−ANCAの特異反応も抑制する
ため、本発明の目的を満たすものではない。これより、
緩衝液の有効pH領域はpH2〜5である。この範囲に
おいて上記緩衝液はC−ANCA含有ヒト血清の測定値
には影響を与えることなく、MPO−ANCA含有ヒト
血清の測定値のみを低下させる効果がある。
The value of MPO-ANCA-containing human serum in the C-ANCA measuring reagent not adjusted to pH was 0.848.
(Comparative Example 1) , the buffering solution has an inhibitory effect from pH 5 or less . On the other hand, when the buffer is adjusted to a strong acid having a pH of 1, the nonspecific reaction of MPO-ANCA is remarkably suppressed, but the specific reaction of C-ANCA is also suppressed, which does not satisfy the object of the present invention. Than this,
The effective pH range of the buffer is pH 2-5. The buffer in this range without affecting the measurement of C-ANCA containing human serum, MPO-ANCA containing human
It has the effect of lowering only serum measurements.

【0015】〔実施例2〕 正常ヒト好中球由来のC−ANCA抗原をマイクロプレ
ート(96ウェル)に固定したものを用意した。クエン
酸ナトリウム-リン酸二水素ナトリウム緩衝液をpH3
〜6に、塩化カリウム-塩酸緩衝液をpH2に調整し
た。これらを200μl/ウェルずつマイクロプレートに
分注し、25℃で0時間、0.5時間、1時間、3時間
インキュベーションした。以下、実施例1と同様の手順
により測定した。反応時間が0時間の結果を表2に、
0.5時間の結果を表3に、1時間の結果を表4に、3
時間の結果を表5に示す。
[ Example 2] A C-ANCA antigen derived from normal human neutrophils immobilized on a microplate (96 wells) was prepared. PH 3 sodium citrate-sodium dihydrogen phosphate buffer
In ~ 6, the pH of the potassium chloride-hydrochloric acid buffer was adjusted to 2. These were dispensed at 200 μl / well into a microplate and incubated at 25 ° C. for 0 hour, 0.5 hour, 1 hour, and 3 hours. Hereinafter, the measurement was performed in the same procedure as in Example 1. Table 2 shows the results when the reaction time is 0 hour.
Table 3 shows the results of 0.5 hour, and Table 4 shows the results of 1 hour.
Table 5 shows the time results.

【0016】[0016]

【表2】 [Table 2]

【0017】[0017]

【表3】 [Table 3]

【0018】[0018]

【表4】 [Table 4]

【0019】[0019]

【表5】 [Table 5]

【0020】表1〜5から明らかなように、pHを2〜
5に調製した緩衝液は、反応時間が0時間(反応直後)
からC−ANCAと共存するMPO抗原を抑制する効果
をもち、反応時間の経過に伴いより高い抑制効果があ
る。よってMPO抗原による非特異反応を抑制するため
に緩衝液を用いる場合は、MPO抗原による非特異反応
の程度により、pHのみならず反応時間も考慮する必要
がある。
As is clear from Tables 1 to 5 , the pH was adjusted to 2
The buffer prepared in 5 had a reaction time of 0 hour (immediately after the reaction).
Has an effect of suppressing MPO antigen coexisting with C-ANCA, and has a higher inhibitory effect as the reaction time elapses. Therefore, when a buffer is used to suppress the non-specific reaction due to the MPO antigen, it is necessary to consider not only the pH but also the reaction time depending on the degree of the non-specific reaction due to the MPO antigen.

【0021】〔比較例1〕 実施例1で非特異反応抑制剤としてpH調製したクエン
酸ナトリウム-リン酸二水素ナトリウム緩衝液または塩
化カリウム-塩酸緩衝液の分注を除き、従来のC−AN
CA測定試薬で、C−ANCA含有ヒト血清、MPO−
ANCA含有ヒト血清および健常人の血清を検体とし
て、実施例1と同様な手順で測定した。その結果を表6
に示す。
Comparative Example 1 A conventional C-AN was prepared in the same manner as in Example 1 except that a sodium citrate-sodium dihydrogen phosphate buffer or a potassium chloride-hydrochloric acid buffer prepared as a nonspecific reaction inhibitor was dispensed.
CA measurement reagent, C-ANCA-containing human serum, MPO-
ANCA-containing human serum and healthy human serum were used as samples and measured in the same manner as in Example 1. Table 6 shows the results.
Shown in

【0022】[0022]

【表6】 [Table 6]

【0023】この結果から、健常人血清の測定値より平
均値+2×SD(標準偏差)を正常値とすると、正常値
は(0.009+2 ×0.00028 =0.00956)であるから、C−A
NCA含有ヒト血清およびMPO−ANCA含有ヒト血
清は正常値との間に明らかに差がある。これは、C−A
NCA抗原を固相化させたウェルに対して、血清中の
PO−ANCAが反応していることから、C−ANCA
抗原と共存するMPO抗原との反応が起こっていると
えられる
From these results, assuming that the average value + 2 × SD (standard deviation) is the normal value from the measured value of the serum of a healthy person, the normal value is (0.009 + 2 × 0.00028 = 0.00956).
There is a clear difference between NCA-containing human serum and MPO-ANCA-containing human serum from normal values. This is CA
The NCA antigen to the wells was immobilized, M in the serum
Since PO-ANCA is reacting, C-ANCA
It is thought that the reaction with the MPO antigen coexisting with the antigen has occurred.
Can be obtained .

【0024】[0024]

【発明の効果】本発明の測定方法を採用すれば、試薬中
C−ANCA抗原の活性を失活させることなくMPO
抗原の非特異反応を抑制できる。つまり、C−ANCA
抗原と共存するMPO抗原だけを特異的に抑制し、目的
とするC−ANCAの正確な測定が可能となる。
According to the measurement method of the present invention, the reagent
MPO without inactivating the activity of C-ANCA antigen
Nonspecific reaction of antigen can be suppressed. That is, C-ANCA
Only the MPO antigen coexisting with the antigen is specifically suppressed, and the desired C-ANCA can be accurately measured.

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 抗原抗体反応において抗好中球細胞質抗
体の抗原と共存するミエロペルオキシダーゼ抗原をpH
2〜5に調製した緩衝液で特異的に抑制することを特徴
とする抗好中球細胞質抗体の測定方法。
In the antigen-antibody reaction, a myeloperoxidase antigen coexisting with an antigen of an anti-neutrophil cytoplasmic antibody is subjected to pH
A method for measuring an anti-neutrophil cytoplasmic antibody, wherein the antibody is specifically inhibited by a buffer prepared in any one of 2 to 5.
JP08748494A 1994-04-01 1994-04-01 Anti-neutrophil cytoplasmic antibody measurement method Expired - Fee Related JP3227690B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP08748494A JP3227690B2 (en) 1994-04-01 1994-04-01 Anti-neutrophil cytoplasmic antibody measurement method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP08748494A JP3227690B2 (en) 1994-04-01 1994-04-01 Anti-neutrophil cytoplasmic antibody measurement method

Publications (2)

Publication Number Publication Date
JPH07280807A JPH07280807A (en) 1995-10-27
JP3227690B2 true JP3227690B2 (en) 2001-11-12

Family

ID=13916227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP08748494A Expired - Fee Related JP3227690B2 (en) 1994-04-01 1994-04-01 Anti-neutrophil cytoplasmic antibody measurement method

Country Status (1)

Country Link
JP (1) JP3227690B2 (en)

Also Published As

Publication number Publication date
JPH07280807A (en) 1995-10-27

Similar Documents

Publication Publication Date Title
JPH02503029A (en) Use of polyoxyethylene ethers to improve the performance of immunoassays using peroxidase conjugates
CN111610335A (en) Time-resolved fluorescence immunochromatographic test strip, kit containing time-resolved fluorescence immunochromatographic test strip and application of time-resolved fluorescence immunochromatographic test strip
CA1340973C (en) Immunometric assay kit and method applicable to whole cells
JP2004301684A (en) Dilution liquid for norovirus or sapovirus specimen, and virus detection reagent
EP4130741A1 (en) Method for immunoassay of amyloid beta in blood, and kit for same
EP1887358A1 (en) Method of immunologically analyzing plasmin degradation product of stabilized fibrin
CN112698041A (en) Compound, growth differentiation factor 15 detection kit thereof and application
WO2017211314A1 (en) Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
CN117233378B (en) Fluorescent immunochromatography test strip for quantitative detection of antibody and preparation method thereof
JP2003279577A (en) Composition for flow through type inspection, and kit using the same, and inspection method
JP3227690B2 (en) Anti-neutrophil cytoplasmic antibody measurement method
EP0811165B1 (en) Detection of antibody production
KR20010025027A (en) Immunoassay reagents and immunoassay method
JPH05508078A (en) Analyzer and method for detecting chitin
CN111208292B (en) Mycoplasma pneumoniae antibody IgM immunoassay kit, preparation method and use method thereof
EP0398292B1 (en) Diagnostic composition for rheumatoid arthritis
EP1192469B1 (en) Assay
CN112710841A (en) ST2 protein detection kit and detection method
CN111239411A (en) Immunodetection kit for mycoplasma pneumoniae antibody IgG, preparation method and use method thereof
JP3227689B2 (en) Anti-neutrophil cytoplasmic antibody measurement method
JP3536191B2 (en) Human lactoferrin analysis method, infectious disease screening method and screening kit
JPH0212062A (en) Biological specificity assay using induced glass surface
JPH09189698A (en) Immunoassay
WO2004048976A1 (en) Method of inspecting staphylococcus aureus
US5593898A (en) Diagnostic method for the immunological determination of NCAM

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees